ArticleClinical and translational science2025
Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04166942 (A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment
Who cites it
1 citing paper in PubMed.
- Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Belumosudil, an orally administered Rho-associated coiled-coil-containing protein kinase 2 selective inhibitor drug for treatment of chronic graft-versus-host disease (GVHD), is predominantly eliminated via the liver. This phase 1, open-label, non-randomized, parallel-group study (NCT04166942) evaluated belumosudil pharmacokinetics and safety after a single 200-mg dose in participants with mild, moderate, or severe hepatic impairment (Child-Pugh classification), matched with healthy participants with normal hepatic function. M1 and M2 metabolites were also assessed. Geometric least squares mean (GLSM) ratios (90% confidence intervals [CI]) for belumosudil area under the plasma concentration-time curve (AUC) from time 0 to the time to infinity (AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.